ESSA Pharma Inc
NASDAQ:EPIX
ESSA Pharma Inc
Net Income (Common)
ESSA Pharma Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ESSA Pharma Inc
NASDAQ:EPIX
|
Net Income (Common)
$-25.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Zymeworks Inc
NYSE:ZYME
|
Net Income (Common)
$-118.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Net Income (Common)
$-94.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Net Income (Common)
$-78m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-40%
|
|
Sunshine Biopharma Inc
OTC:SBFM
|
Net Income (Common)
$-4.5m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-6%
|
See Also
What is ESSA Pharma Inc's Net Income (Common)?
Net Income (Common)
-25.8m
USD
Based on the financial report for Dec 31, 2023, ESSA Pharma Inc's Net Income (Common) amounts to -25.8m USD.
What is ESSA Pharma Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-16%
Over the last year, the Net Income (Common) growth was 21%. The average annual Net Income (Common) growth rates for ESSA Pharma Inc have been -1% over the past three years , -16% over the past five years .